Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

Fig. 3

NK-mediated lysis of BRCA wildtype prostate carcinoma cells treated with olaparib is further increased by the addition of ADCC-mediating antibodies. a Real-time impedance-based assay of BRCA WT prostate carcinoma (DU145) cells in the presence or absence of olaparib (ola), human NK cells, and mAbs. b Lysis of BRCA WT cells with or without olaparib pretreatment and NK cells, and with cetuximab (cet) or isotype control at 12 h and 36 h. c Lysis of DU145 cells with or without 24 h pretreatment with olaparib and NK cells, with either avelumab (ave) or isotype control at 12 h and 36 h. These experiments were performed with four different human NK donors with similar results. p < 0.01**, p < 0.0001****

Back to article page